Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Beam Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Beam Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (BEAM) has a FCF Margin % of -13,981.63% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #596 out of 953 companies in the Biotechnology industry, placing it in the top 62.5%.
Is Beam Therapeutics' FCF Margin % too high?
Beam Therapeutics' current FCF Margin % is -13,981.63%. Based on the distribution chart, Beam Therapeutics ranks #596 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' FCF Margin % compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #596 out of 953 companies for FCF Margin %. This places Beam Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current FCF Margin % is -13,981.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $27.86, compared to a current price of $27.48 — trading 1.4% below its estimated fair value. The current FCF Margin % is -13,981.63%. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current FCF Margin % is -13,981.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of $27.48 is trading 1.4% below its estimated GF Value™ of $27.86.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for BEAM:
FCF Margin %: -13,981.63%
GF Value™: $27.86 vs. price of $27.48 (1.4% below fair value)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score
Get the complete analysis for BEAM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
